MedTrace Logo

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

NCT04787848 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-01-14

No results posted yet for this study

Summary

To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV

Conditions

  • Chronic Widespread Pain

Interventions

DRUG

Relistor Injectable Product

Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation

Sponsors & Collaborators

  • Florida International University

    lead OTHER

Principal Investigators

  • Saurabh Aggarwal, MD., PhD · Florida International University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2026-07-30
Completion
2026-07-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04787848 on ClinicalTrials.gov